FDA Inspection
Bioreliance CorporationBioreliance Corporation – FDA Inspection, Jan 29, 2026
Record Details
This FDA Inspection record concerns Bioreliance Corporation, with an inspection on January 29, 2026, issued by the Baltimore District Office, covering human drugs.
View Company Profile
ID · e199758b-3727-437f-82a7-ea444bde9780
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1295306
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring: Human Drugs
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 58.33(a)Study director: follow study protocol
- 21 CFR 58.33(c)Study director: unforeseen circumstances
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Bioreliance Corporation
11| Date | Classification | Office | Project area |
|---|---|---|---|
| November 22, 2024 | VAI | Baltimore District Office | Vaccine, Allergenic, and Live Biotherapeutic Products |
| August 4, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 8, 2019 | Not classified | Baltimore District Office | |
| July 13, 2018 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| January 11, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Bioreliance Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.